OculusGen Biomedical

OculusGen Biomedical is a clinical-stage biopharmaceutical company dedicated to developing next-generation therapies for sight-threatening ocular diseases. The company utilizes a proprietary bispecific antibody platform to create multi-targeted biologics that address complex disease pathways in retinal and corneal disorders. Its lead program, OCUL-101, is a bispecific antibody targeting both Vascular Endothelial Growth Factor (VEGF) and Complement C5, currently undergoing Phase 1/2 clinical evaluation for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Beyond its antibody pipeline, the company maintains strategic interests in regenerative medicine and medical devices through partnerships with ACRO Biomedical. OculusGen Biomedical is headquartered in Shenzhen, China, with significant operations and historical roots in Taiwan's biotechnology sector.